Reference research describes a comparison population
A study measured IGF-1 using six immunoassays in a large healthy adult cohort and developed reference intervals by age and sex. Even with the same source population, upper reference limits differed substantially among methods. Agreement between methods was moderate to good rather than perfect. [1]
The key distinction is between describing a distribution and choosing a treatment target. A reference interval tells clinicians how a measurement compares with a defined population under a particular method. It does not independently establish which value will produce the best sleep, strength or longevity for an individual.
The upper boundary is not a finish line
Our interpretation is that viewing a laboratory interval as a scoreboard invites a category error. A person near one end of a distribution is not thereby closer to a universal ideal. To justify a target, evidence would need to connect that target with the clinical objective and the balance of benefit and harm.
This matters when a service presents a youthful-looking range as something everyone should pursue. The range may be visually persuasive while answering a different question from the one relevant to treatment. Ask where the target came from and what outcome evidence supports its use for the actual prescription.
Why standardization does not remove every difference
The comparison used the same cohort to evaluate multiple methods. [1] That is an important design feature: differences cannot simply be dismissed as different groups of people. The findings show why a familiar test name does not guarantee complete interchangeability of results.
For a reader, the practical response is to preserve method information and ask how serial results will be interpreted. Our laboratory-disagreement guide covers that comparison directly. A clinician may find a result informative even when it cannot be lined up mechanically with a number from another laboratory.
Match the interpretation to the clinical question
A diagnostic evaluation, treatment monitoring and a wellness advertisement may all mention IGF-1 while using it for different purposes. Ask which purpose applies in your case. The correct explanation should connect the result to a decision rather than merely label it low, high or optimal.
Our biomarker guide separates a laboratory response from a patient benefit. If a proposed sermorelin plan relies on repeated testing, clarify what other outcomes will be reviewed and what uncertainty remains when the number changes. A reference interval is useful context for that discussion, not a self-treatment instruction or a promise that moving upward will improve health.
The percentile boundaries used for a reference distribution are statistical descriptions. They should not be repurposed as evidence that a person closer to an upper boundary receives more benefit, because that would require a different outcome-based investigation.